FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For the month of September 1999
Commission File Number 0-29350
VASOGEN INC.
(Translation of Registrant's name into English)
2155 Dunwin Drive, Suite 10, Mississauga, Ontario, L5L 4M1
(Address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20 - F or Form 40 - F.)
Form 20 - F [X] Form 40 - F [ ]
(Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.)
Yes [ ] No [X]
This Form 6-K consists of:
A press release issued by Vasogen Inc. on September 8, 1999, titled:
"Terrance H. Gregg Appointed to Vasogen's Board of Directors"
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VASOGEN INC.
By /s/Christopher Waddick
-------------------------------------
(Name: Christopher Waddick)
(Title: Vice-President, Finance & CFO)
Date: September 22, 1999
<PAGE>
Vasogen Inc.
INVESTOR CONTACT
2155 Dunwin Drive, Suite 10
Mississauga, ON, Canada L5L 4M1 Trevor Burns
tel (905) 569-2265 fax (905) 569-9231 Investor Relations
http://www.vasogen.com tel (905) 569-9065
e-mail [email protected]
- --------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE
TERRANCE H. GREGG APPOINTED TO VASOGEN'S BOARD OF DIRECTORS
TORONTO, Ontario, (September 8, 1999) -- Vasogen Inc. (TSE:VAS; OTC BB:VSOGF) is
pleased to announce, subject to regulatory approval, the appointment of Terrance
H. Gregg of Los Angeles, California to its Board of Directors.
Mr. Gregg is the President and Chief Operating Officer of MiniMed Inc., a world
leader in diabetes management systems. Since being promoted to President and COO
in 1996, Mr. Gregg has led MiniMed to a four-fold increase in revenue and a
15-fold increase in market capitalization, currently at $2.7 billion.
Prior to joining MiniMed in 1994, Mr. Gregg served in executive positions with
Smith & Nephew plc., a diversified health care product company, and Allergan
Inc., a leading ophthalmic device and pharmaceutical company. He currently
serves as a Health Advisory Board Member of the School of Policy, Planning and
Development at the University of Southern California, and as an Advisory Council
Member of the San Fernando Valley Economic Research Center at the California
State University Northridge.
Dr. William Cochrane, Vasogen's Chairman stated: "We are delighted by Mr.
Gregg's decision to join our Board. He brings a valuable combination of
healthcare and public market experience that will greatly assist the Company as
it enters the United States."
Vasogen is developing proprietary immune modulation therapies to advance
the treatment of cardiovascular, autoimmune and related inflammatory
diseases. These therapies are designed to target fundamental
disease-causing events, providing safe, effective treatment.
Statements contained in this press release, including those pertaining to
scientific and clinical research, commercialization plans, strategic alliances,
and intellectual property protection, other than statements of historical fact,
are forward-looking statements subject to a number of uncertainties that could
cause actual results to differ materially from statements made.
